66
Views
5
CrossRef citations to date
0
Altmetric
Case Reports

Tiagabine augmentation to fluvoxamine–risperidone combination in the treatment of obsessive-compulsive disorder

, MD, , , , , & show all
Pages 953-955 | Received 29 Jul 2007, Published online: 08 Dec 2009

References

  • American Psychiatric Association. 1994. Diagnostic and statistical manual of mental disorders4th ed DSM-IV. Washington, DC: American Psychiatric Association.
  • Arnold PD, Sicard T, Burroughs E, Richter MA, Kennedy JL. Glutamate transporter gene SL1A1 associated with obsessive-compulsive disorder. Arch Gen Psychiatry 2006; 63: 769–776
  • Carpenter LL, Schecter JM, Tyrka AR, et al. Open-label tiagabine monotherapy for major depressive disorder with anxiety. J Clin Psychiatry 2006; 67: 66–71
  • Coric V, Taskiran S, Pittenger C, et al. Rizulole augmentation in treatment-resistant obsessive-compulsive disorder: an open label trial. Biol Psychiatry 2005; 58: 424–428
  • Dickel DE, Veenstra-Vande Weele J, Cox NJ, et al. Association testing of the positional and functional candidate gene SLC1A1/EAAC1 in early onset obsessive-compulsive disorder. Arch Gen Psychiatry 2006; 63: 778–785
  • Dunlop BW, Papp L, Garlow ST, Weiss PS, Knight BT, Ninan PT. Tiagabine for social anxiety disorder. Hum Psychopharmacol 2007; 22: 241–244
  • First MB, Spitzer RL, Williams JB. Structured clinical interview for DSM-IV axis I disorders (clinical version) SCID-I. American Psychiatric Publishing Inc, Washington, DC 1997
  • Goodman WK, Price LH, Rasmussen SA, et al. The Yale-Brown Obsessive Compulsive Scale. I. Development, use and reliability. Arch Gen Psychiatry 1989; 46: 1006–1011
  • Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol 1959; 32: 50–55
  • Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 62–65
  • Jenike MA. Clinical practice. Obsessive-compulsive disorder. New Eng J Med 2004; 350: 259–265
  • Pittenger C, Krystal JH, Coric V. Glutamate-modulating drugs as novel pharmacotherapeutic agents in the treatment of obsessive-compulsive disorder. NeuroRx 2006; 3: 69–81
  • Rosenthal M. Tiagabine for the treatment of generalized anxiety disorder: a randomized, open label, clinical trial with paroxetine as a positive control. J Clin Psychiatry 2003; 64: 1245–1249
  • Schwartz TL, Nihalani N. Tiagabine in anxiety disorders. Expert Opin Pharmacother 2006; 7: 1977–1987
  • Schwartz TL, Azhar N, Husain J, et al. An open-label study of tiababine as augmentation therapy for anxiety. Ann Clin Psychiatry 2005; 17: 167–172
  • Stahl SM. Anticonvulsants as anxiolytics, part 1: tiagabine and other anticonvulsants with actions on GABA. J Clin Psychiatry 2004; 65: 291–292
  • Zwanzger P, Rupprecht R. Selective GABAergic treatment for panic? investigations in experimental panic induction and panic disorder. J Psychiatry Nieurosci 2005; 30: 167–175

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.